Enanta Pharmaceuticals, Inc. (ENTA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ENTA Revenue Growth
Revenue Breakdown (FY 2025)
ENTA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
ENTA Revenue Analysis (2014–2025)
As of May 8, 2026, Enanta Pharmaceuticals, Inc. (ENTA) generated trailing twelve-month (TTM) revenue of $67.0 million, reflecting solid growth of +9.8% year-over-year. The most recent quarter (Q1 2026) recorded $18.6 million in revenue, up 23.1% sequentially.
Looking at the longer-term picture, ENTA's 5-year compound annual growth rate (CAGR) stands at -11.8%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $206.6 million in 2018.
Revenue diversification analysis shows ENTA's business is primarily driven by Royalty (100%). With over half of revenue concentrated in Royalty, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+78.3% YoY), ARQT (+95.3% YoY), and PRTA (-58.0% YoY), ENTA has underperformed the peer group in terms of revenue growth. Compare ENTA vs AGIO →
ENTA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ENTACurrent | $67M | +9.8% | -11.8% | -130.7% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
ENTA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $65.3M | -3.4% | $60.7M | 93.0% | $-85,349,000 | -130.7% |
| 2024 | $67.6M | -14.6% | $67.6M | 100.0% | $-121,691,000 | -179.9% |
| 2023 | $79.2M | -8.1% | $79.2M | 100.0% | $-137,207,000 | -173.2% |
| 2022 | $86.2M | -11.2% | $86.2M | 100.0% | $-123,844,000 | -143.7% |
| 2021 | $97.1M | -20.7% | $97.1M | 100.0% | $-109,573,000 | -112.9% |
| 2020 | $122.5M | -40.3% | $122.5M | 100.0% | $-41,639,000 | -34.0% |
| 2019 | $205.2M | -0.7% | $205.2M | 100.0% | $36.7M | 17.9% |
| 2018 | $206.6M | +101.0% | $206.6M | 100.0% | $88.3M | 42.7% |
| 2017 | $102.8M | +16.5% | $102.8M | 100.0% | $24.6M | 23.9% |
| 2016 | $88.3M | -45.1% | $88.3M | 100.0% | $30.8M | 34.9% |
See ENTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ENTA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ENTA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonENTA — Frequently Asked Questions
Quick answers to the most common questions about buying ENTA stock.
Is ENTA's revenue growth accelerating or slowing?
ENTA maintains +9.8% revenue growth, in line with its 5-year CAGR of -11.8%. TTM revenue stands at $67M. Growth rate remains consistent with historical average.
What is ENTA's long-term revenue growth rate?
Enanta Pharmaceuticals, Inc.'s 5-year revenue CAGR of -11.8% reflects the sustained expansion pattern. Current YoY growth of +9.8% is near this long-term average.
How is ENTA's revenue distributed by segment?
ENTA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.